News & Notes > Screening Procedures on medRxiv
Screening Procedures on medRxiv
medRxiv | 2022-06-13
To increase the transparency of medRxiv’s manuscript screening process, we describe here the requirements for submission and details of how submitted manuscripts are dealt with. We hope this information, together with our site FAQs, will help authors prepare manuscripts that can be handled with minimal delay.
Overview of the screening process:Manuscripts submitted to medRxiv undergo two screening steps. First, in-house screening staff with scientific and editorial expertise check that the details inputted during submission are complete - e.g., the authors have included the appropriate information in the submission fields, special characters are coded correctly, and any group authors are not incorrectly listed as individual authors. The in-house screeners also ensure the manuscript itself is within scope (see below) and an appropriate article type: a research manuscript or clinical research design protocol is acceptable; a narrative review, commentary, opinion piece, or a case report/case series is not (a full list of appropriate article types can be found in our FAQ). In addition, they check for:
- Appropriate details of ethical oversight approval/exemption by an independent entity dedicated to the ethical oversight of research studies
- Information that could potentially identify patients or research participants (e.g., photographs, exact age, location, identifying medical conditions, travel histories, family relationship identifiers, or identifying pedigree data)
- Presence of a clinical trial ID for clinical or educational interventions. We deem a clinical trial to be any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the relationship between a health-related intervention and a health outcome.
Submissions also undergo automated text analyses to identify potential plagiarism and/or material that has already appeared online (e.g., in a journal or on another preprint server).
The second screening stage is the responsibility of volunteer clinicians and health professionals known as medRxiv Affiliates. Affiliates consider two main questions: Does the manuscript present health-related research (i.e. is it a clinical research manuscript that includes methods and data)? And is there potential for public harm from posting it as a preprint? If Affiliates conclude the submission is not health-related research or they have concerns about the content, the submission is flagged for further discussion in-house.
Manuscript escalationManuscripts can be escalated at any stage in the screening process for discussion by the Content Team and, where needed, the medRxiv Founders and individual Affiliates or external advisors. Submissions can be escalated for a number of reasons, for example:
- If the article type or content does not appear to be in scope (e.g., it is a narrative review, or is not considered clinical)
- If the submission does not appear to include an appropriate ethics declaration
- If the manuscript contains potentially identifying information
- If a clinical trial has not been registered in a recognized clinical trial registry
- If the manuscript contains content or conclusions that may cause harm to the public (e.g., if it might encourage reduced compliance with critical public health measures).
The screening process typically takes 2–4 days, but can take longer over weekends and holidays, or if the submission requires in-house discussion and further correspondence with authors. Authors should note that manuscripts cannot be posted at a specific date or time, or their release embargoed according to a requested schedule.